Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti‐tumour T‐cell activation – <scp>IRE</scp> ‐ <scp>IMMUNO</scp> study

Irreversible electroporation induces a PCa-specific systemic immune response in patients with localised PCa, aiding conversion of the tumour microenvironment into a more immune permissive state. Therapeutic efficacy might be further enhanced by combination with CTLA-4 checkpoint inhibition, potentially opening up a new synergistic treatment paradigm for high-risk localised or (oligo)metastatic disease.

Authors

Institutions

Publication Details

Journal
British Journal of Urology
Published
2024-08-05
DOI
https://doi.org/10.1111/bju.16496
Citations
11
Primary Topic
Microbial Inactivation Methods
Type
article
Field-Weighted Citation Impact
4.25

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti‐tumour T‐cell activation – IRE ‐ IMMUNO study

Shikha Agrawal, Bart Geboers, Phillip D. Stricker, Matthijs J. V. Scheltema et al.
11 citations
British Journal of Urology
Microbial Inactivation Methods
4.25
article

Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti‐tumour T‐cell activation – IRE ‐ IMMUNO study

Shikha Agrawal, Bart Geboers, Phillip D. Stricker, Matthijs J. V. Scheltema, Martijn R. Meijerink, Paul Doan, William Gondoputro, Susan J. Clark, Jayne Matthews, Joyce Bakker, Alexandar Blazevski, James Thompson, Tanja D. de Gruijl, Athos Katelaris, Florentine E. F. Timmer, Jason J. Jung, Xanthe Cerutti, Anne‐Maree Haynes, Tim Robertson
article en
11 citations

Abstract

Irreversible electroporation induces a PCa-specific systemic immune response in patients with localised PCa, aiding conversion of the tumour microenvironment into a more immune permissive state. Therapeutic efficacy might be further enhanced by combination with CTLA-4 checkpoint inhibition, potentially opening up a new synergistic treatment paradigm for high-risk localised or (oligo)metastatic disease.

British Journal of UrologyVol. 135(2)
Prostate Cancer Foundation of Australia (AU), Garvan Institute of Medical Research (AU), St. Antonius Ziekenhuis (NL), Amsterdam University Medical Centers (NL), The Kinghorn Cancer Centre (AU), Vrije Universiteit Amsterdam (NL)
Paul Ramsay Foundation, Cancer Center Amsterdam
Openalex Percentile: Top 6%
Microbial Inactivation Methods
4.25
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.